Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT04278898
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
3 Years - 12 Years
Healthy Volunteers
Not accepted

Interventions

  • N-Acetylcysteine — DRUG
    N-acetylcysteine Single Dose 2700 mg taken orally

Study Details

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC.

Key Dates

Start date
Feb 12, 2021
Status verified
May 2026
Primary completion
Jul 31, 2028
Completion
Jan 31, 2029

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: N-acetylcysteine then Placebo
  • Experimental: Placebo then N-acetylcysteine

Primary Outcome Measure

Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI) [ Time Frame: 1 hour after single dose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305
Ramy Chebbo
[email protected]
(650) 723-7845
Hegarty, PhD
[email protected]
(650) 723-7845

Find similar trials in Stanford, CA

By condition
Autism spectrum disorder
By specialty
Pediatrics
By research site
Stanford University School of Medicine· Stanford, CA

Related Studies